miércoles, 3 de octubre de 2018

Cystic Fibrosis News Today Weekly Digest


Cystic Fibrosis Weekly Update

Contents:

Agreement Readies Denmark, Austria for Approval of Vertex CF Therapies

Oct 03, 2018 07:00 am | Diogo Pinto



Vertex agreementVertex Pharmaceuticals has entered a partnership with the Danish pharmaceutical organization Amgros to one day make Vertex’s cystic fibrosis (CF) therapies available for Danish patients. The collaboration was made through an access contract, a first-of-its-kind contract that gives Danish CF patients access to all Vertex’s current and future CF drugs after their regulatory approval. The contract was […]
The post Agreement Readies Denmark, Austria for Approval of Vertex CF Therapies appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike Agreement Readies Denmark, Austria for Approval of Vertex CF Therapies on Facebook

CF Treatments Made Me Deaf, but Sound Is More Beautiful Than Ever Before

Oct 02, 2018 09:00 am | Brad Dell



hearing lossFall 2010 I’ll never forget the morning I couldn’t understand what my friends said as we waited for classes to begin. I’ll never forget calling Mom, phone pressed to my right ear, and not understanding what she said, either. Or my heaving sobs as friends looked on. Or Mom texting me many minutes later to […]
The post CF Treatments Made Me Deaf, but Sound Is More Beautiful Than Ever Beforeappeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike CF Treatments Made Me Deaf, but Sound Is More Beautiful Than Ever Before on Facebook

Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity

Oct 02, 2018 07:30 am | Diogo Pinto



ORC-13661 ototoxicityDecibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational treatment to prevent hearing loss and balance disorders in patients taking high doses of aminoglycoside antibiotics, including cystic fibrosis (CF) patients. Under the terms of the agreement, Oricula will provide scientific advice and support to Decibel throughout the ORC-13661 development process. […]
The post Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity appeared first on Cystic Fibrosis News Today.
Read More
share on TwitterLike Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity on Facebook
 

Recent News

Is It Our Responsibility to Educate Others About CF?
MS1819-SD Shows Positive Results for Exocrine Pancreatic Insufficiency in Phase 2a Trial
In Memory of Serena Lawrence, Who Inspired Voices of the Hurting and Sick
#NACFC — Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study
Vivus Lends Support to CFF Dallas, Forth Worth Chapters’ Recent CF Climb Fundraiser

No hay comentarios:

Publicar un comentario